Autoimmunity, immunologic tolerance, and gene therapy

Immunologic Research

Volumn 17, Issue 1-2, 1998, Pages 33-40

  Chen, Youhai ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anergy; Apoptosis; Autoimmune diseases; Cell death; Deletion; Gene therapy; Immunologic tolerance

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; GENE THERAPY; GENE TRANSFER; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0031918985     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786428     Document Type: Article

References (40)

1. Zamvil SS, Steinman L: The T lymphocyte in experimental allergic encephalomyelitis. Ann Rev Immunol 1990;8:579-621.
2. Farrington M, Grosmaire LS, Nonoyama S, Fischer SH, Hollenbaugh D, Ledbetter JA, Noelle RJ, Aruffo A, Ochs HD: CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci USA 1994;91:1099-1103.
3. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbette RJA, Noelle RJ: In vivo CD40-gp39 interactions are essential for thymus-dependent humoral mmunity II Prolonged suppression of the humoral immune response by an antibody to the ligandfor CD40 gp39. J Exp Med 1993;178:1567-1575.
4. Hollenbaugh D, Ochs HD, Noelle RJ, Ledbetter JA, Aruffo A: The role of CD40 and its ligand in the regulation of the immune response. Immunol Rev 1993;138: 23-37.
5. Gerritse K, Laman JD, Noelle RJ, A A, Ledbetter JA, Boersa WJA, Claassen E: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996;93:2499-2504.
6. Samoilova E, Horton JL, Zhang H, Chen Y: CD40L-blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation. J Mol Med 1997;75:603-608.
7. Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK: CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996;157: 1333-1336.
8. Husby S, Jensenius JC, Svehag SE: Passage of undegraded dietary antigen into the blood of healthy adults Further characterization of the kinetics of uptake and the size distribution of the antigen. Scand J Immunol 1986;24:447-455.
9. Brandtzaeg P, Baklien K, Bjerke K, Rognum TO, Scott H, Valnes K: Nature and properties of the huiman gastrointestinal immune system; in Miller K, Nicklin S (eds): Immunology of the Gastrointestinal Tract. CRC, Boca Raton, FL, 1987, pp. 1-88.
10. Neutra MR, Pringault E, Kraehenbuhl JP: Antigen sampling across epithelial barriers and induction of mucosal immune responses. Ann Rev Immunol 1996;14:275-300.
11. Brandtzaeg P: Overview of the mucosal immune system. Curr Top Microbiol Immunol 1989; 146:13-28.
12. Mowat AM: The regulation of immune responses to dietary protein antigens. Immunol Today 1987;8:93-98.
13. Brandtzaeg P: History of oral tolerance and mucosal immunity. Ann of NY Acad Sci 1996;778:1-27.
14. Nossal GJV: Immunologic tolerance: collaboration between antigen and lymphokines. Science 1989;245:147-153.
15. Teh HS, Kisielow P, Scott B, Kishi H, Uematsu Y, Bluthmann H, von Boehmer H: Thymic major histocompatibiility complex antigens and the alpha beta T-cell receptor determine the CD4/CD8 phenotype of T cells. Nature 1988;335: 229-233.
16. Arnold B, Schonrich G, Hamerling GJ: Multiple levels of peripheral tolerance. Immunol Today 1993;14:15-17.
17. Miller JFAP, Moraham G: Peripheral T cell tolerance. Ann Rev Immunol 1992;10:51-70.
18. Mitchison NA: Specialization tolerance memory competition latency and strife among T cells. Ann Rev Immunol 1992;10:1-12.
19. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL: Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995;376:177-180.
20. Marth T, Strober W, Kelsall BL: High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. J Immunol 1996; 157(6):2348-2357.
21. Chen Y, Kuchroo K, Inobe J-I, Baron JL, Janeway CA, Weiner HL: Oral tolerance in myelin basic protein T-cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996;93:388-391.
22. Kearney ER, Pape KA, Loh DY, Jenkins MK: Visualization of peptide specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994;1:327-339.
23. Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK: Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 c ostimulation and inhibited by CTLA-4. J Immunol 1995;155(3): 1032-1036.
24. Van Houten N, Blake SF: Direct measurement of anergy of antigen-specific T cells following oral tolerance induction. J Immunol 1996;157(4):1337-1341.
25. Egan RM, Yorkey C, Black R, Loh WK, Stevens JL, Woodward JG: Peptide-specific T cell clonal expansion in vivo following immunization in the eye an immune-privileged site. J Immunol 1996; 157:2262-2271.
26. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997;6: 411-417.
27. Chen Y, Inobe J-I, Weiner HL: Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Cell Immunol 1997;178:62-68.
28. Evans CH, Robbins PD: Progress toward the treatment of arthritis by gene therapy. Ann Med 1995; 27(5):543-546.
29. Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchanek MK, Hung GL, Glorioso JC, Robbins PD, Evans CH: Intraarticular expression of biologically active interleukin I-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993;90(22):10,764-10,768.
30. Makarov SS, Olsen JC, Johnston WN, Schwab JH, Anderle SK, Brown RR, Haskill JS: Retrovirus mediated in vivo gene transfer to synovium in bacterial cell wall-induced arthritis in rats. Gene Ther 1995;2(6):424-428.
31. Doherty PJ: Gene therapy and arthritis. J Rheumatol 1995;22(7): 1220-1223.
32. Hung GL, Galea-Lauri J, Mueller GM, Georgescu HI, Larkin LA, Suchanek MK, Tindal MH, Robbins PD, Evans CH: Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synoyium. Gene Ther 1994;1(1):64-69.
33. Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin Jr AS, Haskill JS, Schwab JH: Suppression of experimental arthritis by gene transfer of interleukin I receptor antagonist cDNA. Proc Natl Acad Sci USA 1996; 93(1):402-406.
34. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH: Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996;156(9):3558-3562.
35. Roessler BJ. Allen ED, Wilson JM, Hartman JW, Davidson BL: Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 1993;92(2):1085-1092.
36. Zhang H, Yang Y, Horton JL, Samoilova EB, Judge T, Turka LA, Wilson JM, Chen Y: Amelioration of collagen-induced arthritis by Fas (CD95)-ligand gene transfer. J Clin Invest 1997;100:1951-1957.
37. Wilson JM: Vehicles for gene therapy. Nature 1993;365:691-692.
38. Casscells W, Willerson JT: Amphotropic but not atherotropic: another caveat for adenoviral gene therapy. J Clin Invest 1995;95(6):2425-2426.
39. Kouskoff V, Korganow A-C, Duchatelle V, Degott C, Benoist C, Mathis D: Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87:811.
40. Chen Y, Inobe J-I, Weiner HL: Induction of oral tolerance to MBP in CDS-depleted mice. J Immunol 1995;155:910-916.